Toshifumi Tada, Masayuki Kurosaki, Hidenori Toyoda, Nobuharu Tamaki, Yutaka Yasui, Shinichiro Nakamura, Nami Mori, Keiji Tsuji, Hironori Ochi, Takehiro Akahane, Haruhiko Kobashi, Hideki Fujii, Hiroyuki Marusawa, Masahiko Kondo, Naohito Urawa, Hideo Yoshida, Yasushi Uchida, Atsuhiro Morita, Chitomi Hasebe, Akeri Mitsuda, Chikara Ogawa, Ryoichi Narita, Yoshihito Kubotsu, Tomomichi Matsushita, Masaya Shigeno, Eisuke Okamoto, Kazuhiko Okada, Toyotaka Kasai, Toru Ishii, Michiko Nonogi, Satoshi Yasuda, Yuichi Koshiyama, Takashi Kumada, Namiki Izumi
BACKGROUND AND AIMS: The impact of hepatitis C virus (HCV) eradication via direct-acting antiviral (DAA) therapy on overall mortality, particularly non-liver-related mortality, is understudied. METHODS: We recruited 4180 patients with chronic HCV infection who achieved sustained virological response (SVR) (HCV eradication) through DAA therapy (n = 2501, SVR group) or who did not receive antiviral therapy (n = 1679, non-SVR group); 1236 from each group were chosen using propensity score matching...
September 2, 2024: Liver International: Official Journal of the International Association for the Study of the Liver